TRIA-662
- Generic Name
- TRIA-662
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
Phase 2
Completed
- Conditions
- HypertriglyceridemiaMixed Hyperlipidemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Cortria Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT02008084
- Locations
- 🇨🇦
Dr. Senaratne Professional Corporation, Edmonton, Alberta, Canada
🇨🇦The Bailey Clinic, Red Deer, Alberta, Canada
🇨🇦Rhodin Recherche, Drummondville, Quebec, Canada
The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Cortria Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT01930240
Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Cortria Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT01809301
- Locations
- 🇨🇦
Bio Pharma Services Inc. (BPSI), Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath